POST-TEST

Meet The Professor: Optimizing the Management of Myelodysplastic Syndromes

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **For which of the following categories of myelodysplastic syndromes (MDS) was the oral combination of decitabine and cedazuridine granted FDA approval?**
   a. Previously untreated de novo and secondary MDS with International Prognostic Scoring System (IPSS) risk designations of intermediate-1, intermediate-2 and high
   b. Previously treated de novo and secondary MDS with IPSS risk designations of intermediate-1, intermediate-2 and high
   c. Both a and b

2. **What was the median overall survival in the updated analyses of the Phase III ASCERTAIN study evaluating the oral combination of decitabine and cedazuridine?**
   a. 18.7 months
   b. 24.1 months
   c. >31 months

3. **What is the mechanism of action of magrolimab?**
   a. First-in-class monoclonal antibody against CD47 and macrophage checkpoint inhibitor
   b. Monoclonal antibody against heat shock protein 90
   c. Recombinant humanized anti-CD33 monoclonal antibody

4. **Patients with MDS in which of the following IPSS-R (revised IPSS) risk categories were eligible for the 5F9005 study of magrolimab in combination with azacitidine?**
   a. Low
   b. Low and intermediate
   c. Intermediate to very high

5. **Final results from the Phase Ib trial of the novel TIM-3 targeted antibody sabatolimab combined with a hypomethylating agent included which of the following outcomes in the overall patient cohort with very high or high-risk MDS?**
   a. Durable clinical responses (median duration of response >18 months) with an overall response rate higher than 50%
   b. Durable clinical responses (median duration of response >18 months) with an overall response rate lower than 50%
   c. Short-lived clinical responses (median duration of response <18 months) with an overall response rate higher than 50%
   d. Short-lived clinical responses (median duration of response <18 months) with an overall response rate lower than 50%